Preclinical evaluation for drug resistance
All large pharmaceutical companies assume high risk in attempts to bring drugs to market. More and more can be outsourced to reduce failure risk before the expensive clinical trial. Don’t send a compound into trials blind. Our Gene Mutation Libraries (GMLs) have several applications in the preclinical drug development pipeline: evaluating lead compounds and derivatives and characterizing compounds ready for trials. GMLs from cells treated with and without drugs can identify mutations in binding pockets that are likely to affect efficacy. Comparison to common and disease variants can also guide the selection of compounds for clinical testing.
Why not minimize safety and efficacy concerns before an expensive time-consuming trial?